Anti-CD38 Therapy with Daratumumab for Relapsed/Refractory CD20-Negative Diffuse Large B-Cell Lymphoma Cited by

Fol. Biol. 2020, 66, 17-23

https://doi.org/10.14712/fb2020066010017

Anti-CD38 Therapy with Daratumumab for Relapsed/Refractory CD20-Negative Diffuse Large B-Cell Lymphoma

P. Vockova^1,2, M. Svaton³, J. Karolova^1,2, E. Pokorná², Martin Vokurka², Pavel Klener^1,2

¹1st Department of Medicine – Department of Haematology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
²Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
³CLIP – Laboratory Centre Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic

Received October 15, 2019
Accepted January 21, 2020

Crossref Cited-by Linking

Sohier Pierre, Battistella Maxime, Mouthon Maxime, Fouchardière Arnaud de la, Ortonne Nicolas, Vergara Rémi, Cyrta Joanna, Gros Audrey, Laharanne Elodie, Calonje Eduardo, Menguy Sarah, Lamant Laurence, von Deimling Andreas, Tirode Franck, Pissaloux Daniel, Cribier Bernard, Kervarrec Thibault, Macagno Nicolas: Comprehensive Molecular Profiling of Cribriform Tumors: Identification of Recurrent 6q/9q Codeletion and CD38 Expression. Modern Pathology 2025, 38, 100889. <https://doi.org/10.1016/j.modpat.2025.100889>
Gong Duanhao, Gu Jia, Zhou Kuangguo, Huang Wei: Treatment of Refractory p53 Mutation Large B-cell Lymphoma with Daratumumab and Venetoclax Followed by CAR-T Cell Therapy: Case Report and Animal Study. PRA 2025, 20, 513. <https://doi.org/10.2174/0115748928273058231128073414>
Fallahi Mohammad Sadegh, Zerangian Nasibeh, Ghorbani Atousa, Erabi Gisou, Shirali Melika, Shabani Elaheh, Rommasi Foad, Najafabadi Mahsa Mohammadi, Karbasi Shima, Toutounchian Samaneh, Ahangar-Sirous Ramin, Motaghy Ava, Heidari Mahsa, Deravi Niloofar: Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review. CCTR 2024, 20, 53. <https://doi.org/10.2174/1573394719666230201122212>
Lei Tao, Wu Gongqiang, Xu Yongjin, Zhuang Weihao, Lu Jialiang, Han Shuiyun, Zhuang Yuxin, Dong Xiaowu, Yang Haiyan: Peripheral immune cell profiling of double-hit lymphoma by mass cytometry. BMC Cancer 2023, 23. <https://doi.org/10.1186/s12885-023-10657-0>
Zeng Feng, Zhang Jiani, Jin Xi, Liao Qianjin, Chen Zhifang, Luo Gengqiu, Zhou Yanhong: Effect of CD38 on B‐cell function and its role in the diagnosis and treatment of B‐cell‐related diseases. Journal Cellular Physiology 2022, 237, 2796. <https://doi.org/10.1002/jcp.30760>
Adam Zden\u011bk, Pour Lud\u011bk, Krej\u010dí Marta, Zeman David, \u0158ehák Zden\u011bk, Koukalová Renata, Sandecká Viera, \u0160tork Martin, Král Zden\u011bk: Review of daratumumab efficacy in all monoclonal gammopathies and other diseases and our experience with daratumumab, lenalidomide and dexamethasone therapy in 74 patients. Onkologie 2022, 16, 61. <https://doi.org/10.36290/xon.2022.057>
Ejaz Kiran, Roback John D., Stowell Sean R., Sullivan Harold C.: Daratumumab: Beyond Multiple Myeloma. Transfusion Medicine Reviews 2021, 35, 36. <https://doi.org/10.1016/j.tmrv.2021.06.002>
Gambles M. Tommy, Li Jiahui, Wang Jiawei, Sborov Douglas, Yang Jiyuan, Kopeček Jindřich: Crosslinking of CD38 Receptors Triggers Apoptosis of Malignant B Cells. Molecules 2021, 26, 4658. <https://doi.org/10.3390/molecules26154658>
Lidický Ond\u0159ej, Klener Pavel, Machová Daniela, Vo\u010dková Petra, Pokorná Eva, Helman Karel, Mavis Cory, Janou\u0161ková Olga, Etrych Tomá\u0161: Overcoming resistance to rituximab in relapsed non-Hodgkin lymphomas by antibody-polymer drug conjugates actively targeted by anti-CD38 daratumumab. Journal of Controlled Release 2020, 328, 160. <https://doi.org/10.1016/j.jconrel.2020.08.042>